Q

Quest Diagnostics

Operates nationwide clinical laboratory testing

Health Systems Advanced Pathology Solutions Business Development Executive

Full-Time
$146k - $200k/yr+ Annual performance bonus
Senior
Bachelor's, Master's, MBA
Clifton, NJ, USA
HybridWeekly travel throughout the North and East regions; travel required 50–75%. May reside in New York or New Jersey.
Sales & Account ManagementField Sales

About the job

Requirements
  • Minimum of 7–10 years of successful enterprise sales, strategic account business development, or high-level account management experience in healthcare or diagnostics, with a documented history of quota overachievement.
  • Minimum of 4 years working in a Pathology, Clinical Diagnostics, or Oncology B2B commercial environment managing complex health systems and matrixed customer organizations.
  • Proven experience structuring, negotiating, and executing complex enterprise contracts, scopes of work, and multi-stakeholder commercial agreements.
  • Deep understanding of the diagnostic reference laboratory business model, esoteric clinical tests, and pathology workflows.
  • Strong working knowledge of healthcare industry economics, payor landscapes, and B2B pricing structures.
  • High level of compliance awareness regarding laboratory regulations, including Stark Law and the Anti-Kickback Statute.
  • Bachelor's degree in Business, Marketing, or Life Sciences.
  • Deep understanding of Anatomic Pathology, Oncology, and cancer diagnostics, including IHC, Flow Cytometry, Next-Generation Sequencing, Cytogenetics, Germ-line and Somatic genomics, and minimal residual disease frameworks.
  • In-depth familiarity with hospital pathology department operations, professional versus technical billing components, digital slide scanning and AI integration, and health data interoperability across EHR, LIS, and HIS systems.
  • Strong working knowledge of diagnostic laboratory reimbursement models, commercial and government payer landscapes, hospital margin dynamics, and healthcare policy.
  • Thorough understanding of diagnostic compliance requirements, including HIPAA, the Stark Law, and the Anti-Kickback Statute.
  • Valid driver's license.
  • Ability to travel 50–75%.
Responsibilities
  • Identify, profile, and secure new large-scale health system agreements, academic medical centers, NCCN member institutions, and high-volume specialty networks.
  • Drive strategic adoption of Quest’s Anatomic and Advanced Pathology portfolio, positioning AmeriPath, Dermpath Diagnostics, and esoteric testing services for diagnostic accuracy, clinical quality, and operational efficiency.
  • Lead development of client-centric B2B commercial proposals and Scopes of Work, presenting clinical, operational, and financial value propositions to hospital leadership and executive committees.
  • Identify and support evaluation of strategic mergers and acquisitions and partnership opportunities aligned with Quest Diagnostics and AmeriPath growth objectives.
  • Structure, present, and close complex pathology delivery models, including digital pathology and AI diagnostic enablement tools; technical-only FISH, Flow Cytometry, IHC and Special Stains; subspecialized Hematopathology, solid tumor testing, and reference laboratory send-out consolidation; and genomic and somatic diagnostic pathways supporting NGS, cytogenetics, and MRD strategies.
  • Demonstrate knowledge of hospital and health system pathology workflows and the role of pathologists in oncology diagnoses, therapeutic selection, and multidisciplinary tumor boards; facilitate medical and operational dialogue with C-suite leaders, lab directors, and pathologists.
  • Collaborate with Information Technology to align client workflows across HIS, LIS, and ambulatory EHRs, enabling digital connectivity, compliant order entry, and automated result routing.
  • Partner with regional sales leadership, Advanced Oncology commercial teams, Health Systems counterparts, Medical Science Liaisons, Lab Operations, and Franchise leads to execute unified market development plans.
  • Maintain sales discipline and pipeline sufficiency against corporate metrics, including pipeline volume, C-suite and physician meeting productivity, cross-franchise touchpoints, and closed-won annual contract value.
  • Collect and communicate field insights, voice-of-customer feedback, competitive intelligence, and regulatory and payer trends to Commercial Oncology franchise and brand leadership.
  • Maintain executive relationships across client institutions to protect existing business and foster long-term client loyalty.
  • Lead commercial contract negotiations, strategic renewals, fee adjustments, and price modifications while ensuring compliance with healthcare legal and regulatory standards.
  • Coordinate with Quest Operations, project managers, and onboarding specialists during implementation, then hand off day-to-day coordination to designated Account Management teams.
  • Monitor account health, order patterns, and send-out utilization to mitigate revenue leakage and address operational bottlenecks.
Desired Qualifications
  • Direct commercial experience representing subspecialty pathology laboratory services, such as AmeriPath, Dermpath Diagnostics, or esoteric reference testing.
  • Experience with product launches, market development programs, and consultative methodologies such as Challenger Sales or IMPAX models.
  • A Master's or other advanced degree is preferred, including an MBA, an M.S. in Life Sciences, or another relevant advanced clinical or business degree.

About the company

Quest Diagnostics provides clinical laboratory testing and diagnostic services. It processes patient samples across a network of laboratories to run a broad menu of 3,000+ tests, including cancer diagnostics and anatomical pathology, and delivers interpretive reports through its medical staff. Tests are performed at its patient service centers, esoteric and rapid-response labs, and outpatient facilities, with results shared with clinicians via connected data systems. What sets Quest Diagnostics apart is its scale and scope: the world’s largest clinical lab network, the broadest test menu, a large team of MDs and PhDs for interpretation, and leadership in cancer diagnostics and pre-employment drug testing, plus extensive clinical trials testing. Its goal is to empower healthcare providers and patients with actionable diagnostic insights to identify, treat, and manage disease, inspire healthy behaviors, and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Secaucus, New Jersey

Founded

1967

Get referred to Quest Diagnostics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apple Health users will order Quest tests later in 2026, expanding direct-to-consumer reach.
  • Quest’s consumer-health business reached $250 million in 2025 and management targets 30% 2026 growth.
  • Quest will launch Roche pTau217 and its new multi-biomarker AD-Detect panel in Q4 2026.

What critics are saying

  • CMS cuts lab reimbursement up to 15% on January 1, 2027, hitting CMS revenue.
  • Quest faces NLRB case 14-CA-378210 over alleged discharge and coercive statements in St. Louis.
  • Repeated PAMA cuts and commoditized testing can squeeze Quest into a low-margin processing utility.

What makes Quest Diagnostics unique

  • Quest serves half of U.S. physicians and hospitals through 2,000 service centers.
  • Quest built a consumer-health platform with Apple Health, Oura, Hims & Hers, and Function Health.
  • Quest leads blood-based Alzheimer’s diagnostics with AD-Detect and Roche pTau217 launches in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Performance Bonus
  • Employee Stock Purchase Plan
  • Tuition Reimbursement
  • Wellness Program
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours
  • 401(k) Retirement Plan

Company News

Yahoo Finance
Sep 22nd, 2026
Quest Diagnostics drops 5% as US cuts lab test reimbursement rates by 15%

Quest Diagnostics stock fell 5.1% on Tuesday after the Centers for Medicare and Medicaid Services announced it would cut reimbursement rates for lab work by up to 15%, effective 1 January 2027. CMS disclosed it has been paying approximately 16% more for lab tests than private insurers. The rate cuts could save taxpayers $1 billion annually but will reduce Quest's revenue. The company derives about 11% of its revenue from CMS reimbursement. If rates decrease by the full 15%, Quest's annual revenue would drop by 1.65%. Successive 15% annual reductions are possible through 2029, meaning a worst-case revenue reduction of slightly less than 5%. The company had warned in its SEC filing that Medicare and Medicaid rate changes posed risks to its business.

Citybiz
Sep 14th, 2026
Quanterix names yuri Fesko chief medical officer as diagnostics business expands.

Quanterix names yuri Fesko chief medical officer as diagnostics business expands. September 14, 2026 Dr. Yuri Fesko Quanterix Corporation has appointed Dr. Yuri Fesko chief medical officer, adding an experienced diagnostics executive as the company prepares for a broader market launch of its Lucent AD(R) Complete Alzheimer's disease test and advances regulatory work for its HD-X instrument. Fesko will provide medical and clinical leadership across the Nasdaq-listed precision biomarker company, working with its Diagnostics, Scientific, R&D, Regulatory and Commercial teams. He will be based at Quanterix's headquarters in Billerica, Massachusetts. The newly created role comes as Quanterix works to expand its diagnostics business and move more of its biomarker technologies into clinical applications. President and CEO Everett Cunningham said Fesko's background in clinical affairs and precision medicine will support both the commercialization of Lucent AD Complete and the company's planned IVD filing for HD-X. "As we prepare for the broader market launch of our Lucent AD Complete five biomarker test for Alzheimer's Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our efforts to efficiently scale our expansion in diagnostics," Cunningham said. Fesko most recently served as chief medical officer at Quest Diagnostics, where he oversaw Medical Affairs, Clinical Development, Analytics and Public Health. He also served as the medical lead supporting the company's Quality and Regulatory functions and provided senior medical leadership for pathology and dermatopathology. His experience spans the development and implementation of precision medicine strategies in oncology, metabolic disease, neurology and consumer health. He has worked with health systems, pharmaceutical and biotechnology companies, and physician organizations to integrate precision diagnostics into clinical practice and clinical trials. Fesko also brings experience supporting FDA submissions, clinical development programs, companion diagnostic strategies and reimbursement planning. Those capabilities are relevant as Quanterix works to translate its biomarker research technologies into regulated diagnostic products and expand their use in clinical settings. One immediate priority is Lucent AD Complete, Quanterix's five-biomarker blood test for Alzheimer's disease. The company is preparing for a broader market launch of the test while simultaneously advancing the IVD regulatory filing for its HD-X instrument, making medical, regulatory and commercialization coordination a central part of Fesko's mandate. Cunningham said Fesko's ability to work across medicine, diagnostics, analytics and business strategy will support the company's efforts to build its Diagnostics business and broaden the clinical applications of its technology. Quanterix develops precision biomarker technologies designed to detect and quantify biological markers at very low concentrations. Its Simoa(R) platform provides high-sensitivity biomarker measurement in blood and other fluids, supporting applications across disease research, diagnostics and drug development. The company's technology portfolio has also expanded through its acquisition of Akoya Biosciences. Quanterix Spatial solutions provide high-plex quantitative protein analysis in tissue at single-cell resolution, adding spatial biology capabilities alongside its existing fluid biomarker technologies. Quanterix also operates Accelerator Laboratory services, providing researchers with additional capabilities for moving biomarker discoveries toward diagnostic applications. Together, those businesses give the company a platform spanning biomarker measurement, spatial analysis and laboratory services as it increases its focus on precision diagnostics. Fesko earned both his bachelor's degree and Doctor of Medicine from Case Western Reserve University and completed a fellowship at University Hospitals of Cleveland. He is board-certified in internal medicine, hematology and medical oncology. His appointment adds senior clinical leadership at a point when Quanterix is managing both product commercialization and regulatory execution. As the company expands beyond research applications, Fesko will help coordinate the medical evidence, regulatory strategy and clinical adoption required to move its biomarker technologies more broadly into diagnostic workflows.

PR Newswire
Sep 9th, 2026
Apple Health app users to order lab tests from Quest Diagnostics for $119

Apple Health app users in the United States will be able to purchase laboratory tests from Quest Diagnostics directly through the app later this year. Apple announced the update at its September event. Users can buy a Quest laboratory panel featuring over 50 biomarkers for $119. The panel assesses cardiometabolic health and organ function, including biometric readings for blood pressure, height, weight, and waist and hip circumferences. Customers can schedule blood draws and biometric readings at approximately 2,000 Quest patient service centres across the US. Results will appear in the Apple Health app shortly after testing. Quest collaborates with third-party providers to review test orders and discuss results at no additional charge.

Yahoo Finance
Sep 8th, 2026
Quest Diagnostics CEO sells 10,000 shares for $2.4M under pre-arranged trading plan

J.E. Davis, CEO and President of Quest Diagnostics, sold 10,000 shares of the diagnostic testing company for $2.4 million on 1 September 2026, according to an SEC Form 4 filing. The shares were sold at $242.72 each under a Rule 10b5-1 trading plan. Following the transaction, Davis retains 122,423 shares in the company, valued at $28.9 million. The sale occurred after Quest Diagnostics shares delivered a 32% total return over the preceding 12 months. Quest Diagnostics reported revenue of $11.6 billion and net income of $1.1 billion over the trailing twelve months. The company has a market capitalisation of $26.4 billion.

Ticker Report
Sep 5th, 2026
Man Group plc Makes New $495,000 Investment in Quest Diagnostics Incorporated $DGX

Man Group plc purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,336 shares of the medical research company’s stock, valued at approximately $495,000. Several other hedge funds […]